QUOTE AND NEWS
Business Wire  Jan 14  Comment 
Adolor Corporation (NasdaqGM: ADLR) today announced the following promotions: Michael D. Adelman has been promoted to the position of Vice President, Marketing and Sales. Mr. Adelman, 39, joined Adolor in late 2008 as Senior Director, Marketing where
Business Wire  Nov 12  Comment 
Adolor Corporation (NasdaqGM:ADLR) today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in
StreetInsider.com  Oct 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Adolor+Corp.+%28ADLR%29+Posts+Q3+Loss+of+%240.24%2C+Misses+Estimates/5054471.html for the full story.
FierceBiotech  Sep 22  Comment 
Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor says it will soon launch a new trial for the...
MarketWatch  Aug 21  Comment 
Drug- and biotech-sector benchmarks move higher in tandem with the broader stock market, as Genzyme gain on an analyst upgrade.
Marketwire  Aug 20  Comment 
EXTON, PA and PHILADELPHIA, PA -- (Marketwire) -- 08/20/09 -- Adolor Corporation (NASDAQ: ADLR) and GlaxoSmithKline (NYSE: GSK) today announced that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel
StreetInsider.com  Jul 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Adolor+%28ADLR%29+Reports+In-Line+Q2+Loss+of+%240.36/4826491.html for the full story.



Thank you for your suggestion


 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki